NCT04754594: A reported trial by Biontech SE
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04754594 |
|---|---|
| Title | A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 16, 2021 |
| Completion date | July 15, 2022 |
| Required reporting date | July 15, 2023, midnight |
| Actual reporting date | July 14, 2023 |
| Date last checked at ClinicalTrials.gov | Aug. 11, 2026 |
| Days late | None |